Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Decrease in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 400 shares, a decline of 66.7% from the October 31st total of 1,200 shares. Based on an average daily volume of 81,400 shares, the short-interest ratio is currently 0.0 days.

Bavarian Nordic A/S Trading Up 1.7 %

Shares of BVNRY traded up $0.15 during midday trading on Wednesday, reaching $8.99. 8,831 shares of the stock were exchanged, compared to its average volume of 33,372. The company’s 50 day moving average is $10.38 and its two-hundred day moving average is $9.95. The company has a market capitalization of $2.13 billion, a P/E ratio of 13.42 and a beta of 1.71. Bavarian Nordic A/S has a 52 week low of $6.86 and a 52 week high of $14.60.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.